EVGNHealthcare · BiotechnologyThe 1 Wall Street analysts covering Evogene Ltd. hold a median 12-month price target of $2.15 — +473.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 51 of 100 as at 31 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Evogene Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (93): Smaller than most of the companies we track.
Value (3): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on EVGN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +473.9% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 22 May 2025 | Lake Street | Maintains | Buy | — |
| 22 May 2025 | Lake Street | Maintains | Buy | $5.00 → $3.50 |
| 23 Aug 2024 | Lake Street | Maintains | Buy | — |
| 2 Oct 2023 | Alliance Global Partners | Initiates | Buy | — |
| 18 Aug 2023 | Lake Street | Maintains | Buy | — |
| 21 July 2023 | Roth MKM | Maintains | Buy | — |
| 2 May 2023 | Lake Street | Initiates | Buy | — |
| 12 Sept 2022 | Aegis Capital | Maintains | Buy | — |
| 2 Sept 2022 | Roth MKM | Maintains | Buy | — |
| 8 Oct 2021 | Roth Capital | Initiates | Buy | — |
| 29 July 2021 | Aegis Capital | Initiates | Buy | — |
| 1 Dec 2020 | Cantor Fitzgerald | Initiates | Overweight | — |
| 12 Nov 2014 | Credit Suisse | Maintains | Outperform | $24 → $22 |
| 17 Dec 2013 | Deutsche Bank | Initiates | Buy | — |
| 16 Dec 2013 | Credit Suisse | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
EVGN appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Evogene Ltd. returned −69.5% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 72% of US stocks
Cheaper than 39% of US stocks
Cheaper than 76% of US stocks
Cheaper than 66% of US stocks
Higher than 4% of US stocks
Higher than 8% of US stocks
Higher than 50% of US stocks
Higher than 7% of US stocks
Higher than 23% of US stocks
Higher than 8% of US stocks
Higher than 11% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Evogene Ltd. has a market value of $5.0M and an enterprise value of $6.9M.
Revenue in the twelve months to 30 June 2026: $1.3M. The latest quarter shrank 60.7% year on year.
Net income over the same four quarters: −$7.8M, a −598.3% net margin.
Diluted earnings per share, trailing twelve months: $−0.91.
Free cash flow in the twelve months to 30 June 2026: −$11.0M.
Trailing P/E: 0.3×; forward P/E: −0.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Evogene Ltd. employs 38 people — $34K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Evogene Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Evogene announced acute graft-versus-host disease (aGVHD) as the target indication for its internal AI-driven drug discovery program, which is developing a small-molecule therapeutic.
Why it matters — The announcement identifies the disease area that will guide Evogene’s internal drug-discovery effort.
Evogene announced it will attend BIO-Europe in Cologne, Germany, on November 9–11, 2026, and present a scientific poster at Drug Discovery Chemistry Europe in Barcelona, Spain, on November 10–12, 2026.
Why it matters — The announcement outlines Evogene’s planned participation in two European industry conferences, including a scientific poster presentation.
Evogene announced it will participate in the AI Drug Discovery Roadshow, scheduled for November 2–5, 2026, across the U.S. East Coast. The Israel Export Institute and TradeIL organized the event to connect Israeli AI-driven drug discovery and biotechnology companies with U.S. investors, pharmaceutical companies, and potential strategic partners.
Why it matters — The event could give Evogene opportunities to engage with U.S. investors, pharmaceutical companies, and potential strategic partners.
Evogene announced a comprehensive cooperation agreement with L.I.A. Pure Capital Group to resolve differences and reconstitute the company’s board of directors.
Why it matters — The agreement concerns Evogene’s governance and its relationship with Pure Capital Group.
Evogene Ltd. announced that Nasdaq has granted the company an additional 180-day period to regain compliance with the minimum bid price requirement. The announcement was made from Rehovot, Israel, on Sept. 30, 2026.
Why it matters — EVGN watchers would care because this extended compliance window affects the company's continued listing status on Nasdaq.
The 1 Wall Street analysts covering Evogene Ltd. have a median 12-month price target of $2.15, with estimates ranging from $2.15 to $2.15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering Evogene Ltd., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Evogene Ltd. 51 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Evogene Ltd. ranks 51 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (93 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +473.9% from the last close, and Ticker Nerd's factor model ranks Evogene Ltd. 51 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Evogene Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EVGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.15 to $2.15 over the next 12 months.
Evogene Ltd. returned -69.5% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Evogene Ltd. is a computational biology and chemistry company focused on life-science product discovery and development.
The most recent item we track (PRNewsWire, 28 Oct 2026): "Evogene Announces Acute Graft-Versus-Host Disease (aGVHD) as the Target Indication for Its Internal AI-Driven Drug Discovery Program". Evogene announced acute graft-versus-host disease (aGVHD) as the target indication for its internal AI-driven drug discovery program, which is developing a small-molecule therapeutic.
Evogene Ltd. is a computational biology and chemistry company focused on life-science product discovery and development. Evogene uses its proprietary AI-driven platforms to design and optimize small molecules, seed traits, ag-chemicals, ag-biologicals, and other products for agriculture, human health, and industrial applications. Its current business is organized around three segments: Agriculture, Human Health, and Industrial Applications. In agriculture, the company works on crop-improvement solutions such as seed traits and biological or chemical inputs that support plant performance. In human health, it develops microbiome-based therapeutics and related discovery programs. In industrial applications, it pursues specialized biological and seed-based solutions for non-food uses. Headquartered in Rehovot, Israel, Evogene serves as a technology platform company that applies computational methods to accelerate product discovery across multiple sectors.
CEO Mr. Ofer Haviv CPA · 38 employees · Israel · https://www.evogene.com
